ATAI Life Sciences
Valuation
$2.3B
About ATAI Life Sciences
ATAI Life Sciences develops innovative mental health treatments that address significant unmet medical needs.
Founded
2018-01-01
Industry
Biotechnology, Health Care, Life Science, Mental Health, Therapeutics
Last Funding Type
Post Ipo Debt
Valuation
2.3
Total Funding
$522.10 million dollars
Financial
ATAI Life Sciences is focused on developing treatments for mental health disorders, utilizing compounds like N,N-dimethyltryptamine (DMT) and its crystalline forms, which are explored for their therapeutic potential in mental health diseases. They are also investigating the use of MDMA for stress-related disorders and the therapeutic effectiveness of ibogaine for conditions such as substance abuse. Additionally, ATAI is researching serotonin receptor activators and novel compositions for neurological conditions, highlighting their commitment to addressing unmet medical needs in mental health.
Funding Rounds
11
Number of Lead Investors
9
Total Funding Amount
$522.10 million dollars
Number of Investors
43